Compare ATGL & CMPX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ATGL | CMPX |
|---|---|---|
| Founded | 2017 | 2014 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 241.3M | 203.5M |
| IPO Year | 2023 | 2020 |
| Metric | ATGL | CMPX |
|---|---|---|
| Price | $5.30 | $0.91 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 15 |
| Target Price | N/A | ★ $5.50 |
| AVG Volume (30 Days) | 7.9K | ★ 3.9M |
| Earning Date | 01-27-2027 | 11-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $4.52 | $1.08 |
| 52 Week High | $50.00 | $6.88 |
| Indicator | ATGL | CMPX |
|---|---|---|
| Relative Strength Index (RSI) | 43.03 | 16.38 |
| Support Level | $4.52 | N/A |
| Resistance Level | $7.55 | $2.08 |
| Average True Range (ATR) | 0.61 | 0.09 |
| MACD | 0.14 | -0.07 |
| Stochastic Oscillator | 33.58 | 0.00 |
Alpha Technology Group Ltd operates through its subsidiaries, which are established cloud-based IT solution service providers in Hong Kong. Its Operating Subsidiaries utilize its analytic skills, programming skills, artificial intelligence technologies and technological know-how to provide comprehensive solutions designed to optimize the business performance of customers, meet various industry-specific operational challenges of customers and create new business opportunities for customers. The Operating Subsidiaries provide services for customers from a variety of industries, including consulting, real estate, architectural design, carpark management, electronic payment services, logistics, investments, retail, textiles, wholesale and distribution, etc.
Compass Therapeutics Inc is a clinical-stage oncology-focused biopharmaceutical company that develops proprietary antibody therapeutics to engage the immune system to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to target the immune system and identify optimal combinations empirically broadly. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of the following product candidates; CTX-009, CTX-471, CTX-10726, VEGF-A, Bispecific, and CTX-8371.